SA 187. Mr. WYDEN (for himself and Mr. Sanders) submitted an
amendment intended to be proposed by him to the concurrent resolution
S. Con. Res. 3, setting forth the congressional budget for the United
States Government for fiscal year 2017 and setting forth the
appropriate budgetary levels for fiscal years 2018 through 2026; which
was ordered to lie on the table; as follows:
At the end of title IV, add the following:
SEC. 4__. POINT OF ORDER AGAINST LEGISLATION THAT DOES NOT
LOWER DRUG PRICES.
(a) Findings.--The Senate finds the following:
(1) Total annual drug spending in the United States is
projected to reach more than $500,000,000,000 by 2018.
(2) One out of five Americans age 19 to 64 cannot afford to
fill their prescriptions.
(3) Spending on prescription drugs in the United States
grew by 12 percent in 2014, faster than in any year since
2002.
(4) Medicare part D drug spending was $90,000,000,000 in
2015, and is expected to increase to $216,000,000,000 by
2025.
(5) Medicare part B drug spending also more than doubled
between 2005 and 2015, increasing from $9,000,000,000 in 2005
to $22,000,000,000 in 2015.
(6) In 2014, prescription drug spending in Medicaid
increased by 24 percent.
(7) During the Presidential campaign, the President-elect
said, ``When it comes time to negotiate the cost of drugs,
we're going to negotiate like crazy, folks'' and his campaign
website said that, ``allowing consumers access to imported,
safe and dependable drugs from overseas will bring more
options to consumers.''.
(8) After being elected, the President-elect said, ``I'm
going to bring down drug prices. I don't like what's happened
with drug prices.''.
(9) On January 11, 2017, the President-elect said, ``We
have to create new bidding procedures for the drug industry,
because they are getting away with murder.''.
(b) Point of Order.--It shall not be in order in the Senate
to consider a bill or joint resolution reported pursuant to
section 2001 or 2002, or an amendment to, motion on,
conference report on, or amendment between the Houses in
relation to such a bill or joint resolution that does not, as
promised by the President-elect, lower drug prices as
certified by the Congressional Budget Office.
(c) Waiver and Appeal.--Subsection (b) may be waived or
suspended in the Senate only by an affirmative vote of three-
fifths of the Members, duly chosen and sworn. An affirmative
vote of three-fifths of the Members of the Senate, duly
chosen and sworn, shall be required to sustain an appeal of
the ruling of the Chair on a point of order raised under
subsection (b).